Clinical trials: Cholangiocarcinoma Cancer
Intrahepatic Cholangiocarcinoma, Transarterial Chemoembolization
DEB-TACE Combined With Apatinib and PD-1 for the Treatment of Intrahepatic Cholangiocarcinoma
Intrahepatic cholangiocarcinoma (ICC) is a malignant tumor of biliary epithelial cells that originates from the branches of the intrahepatic bile duct at the second level and above.
- Conditions
- Intrahepatic Cholangiocarcinoma, Transarterial Chemoembolization, Apatinib, PD-1 Antibody
- Trial name
- NCT04834674
- Testing
- DEB-TACE combined with apatinib and PD-1 antibody
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Sichuan Cancer Hospital and Research Institute
Intrahepatic Cholangiocarcinoma
Low-Dose Radiation Therapy to the Whole Liver With Gemcitabine and Cisplatin in IHC
The overall goal of this study is to determine the safety and efficacy of combination treatment of low-dose fractionated radiation therapy with gemcitabine-cisplatin chemotherapy for locally advanced mass forming intra-hepatic…
- Trial name
- NCT02254681
- Testing
- Gemcitabine, Cisplatin, low dose radiotherapy
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Allina Health System
Rare Cancers, Cholangiocarcinoma
TCF-001 TRACK (Target Rare Cancer Knowledge) Study
This open label, non-randomized, multi-center, pragmatic study aims to establish whether patients with rare tumors can benefit from matched molecular therapy as dictated by their next-generation sequencing (NGS) results.
- Conditions
- Rare Cancers, Cholangiocarcinoma, Cancer of Unknown Primary Site
- Trial name
- TRACK (NCT04504604)
- Testing
- FoundationOne CDx and FoundationOne Liquid CDx
- Where
- United States
- Volunteers
- 400 people
- Sponsor
- TargetCancer Foundation
Pancreatic Cancer, Bile Duct Cancer
Effects of Preoperative Immunonutrition in Patients Undergoing Pancreaticoduodenectomy
The purpose of this study is to determine whether preoperative immunonutrition is effective on infectious complication and Th1/Th2 differentiation in patients with pancreaticoduodenectomy.
- Trial name
- EPIPD (NCT01256034)
- Testing
- Oral IMPACT
- Where
- Japan
- Volunteers
- 50 people
- Sponsor
- Chiba University
Breast Cancer, Colorectal Cancer
Vaccine Therapy in Treating Patients With Advanced or Metastatic Cancer
RATIONALE: Vaccines made from a person's white blood cells that have been treated in the laboratory may make the body build an immune response to kill tumor cells.
- Conditions
- Breast Cancer, Colorectal Cancer, Gallbladder Cancer, Gastric Cancer
- Trial name
- NCT00027534
- Testing
- TRICOM-CEA(6D)
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- Michael Morse, MD
Intrahepatic Cholangiocarcinoma
Lenvatinib for Unresectable Intrahepatic Cholangiocarcinoma
The purpose of this study is to evaluate the efficacy and safety of lenvatinib for patients with unresectable intrahepatic cholangiocarcinoma
- Trial name
- NCT03801499
- Testing
- Lenvatinib
- Where
- China
- Sponsor
- Sun Yat-sen University
Hilar Cholangiocarcinoma, Duodenal Neoplasms
Diagnostic Accuracy of Eus Fnb in Difficult to Reach Lesions
The present study aims at comprehensively assessing the diagnostic performance and safety profile of EUS-FNB as a primary diagnostic tool for suspected malignancies in anatomically complex or deeply situated regions, including…
- Trial name
- NCT07621536
- Where
- Italy
- Volunteers
- 131 people
- Sponsor
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Intrahepatic Cholangiocarcinoma (Icc)
A Trial of Apatinib and Adebrelimab in Combination With Chemotherapy in Patients With Unresectable ICC
The study aims to evaluate the efficacy and safety of Apatinib and Adebrelimab in Combination With chemotherapy in patients with advanced intrahepatic cholangiocarcinoma (ICC)
- Trial name
- ACADEMY (NCT06925516)
- Testing
- Apatinib and Adebrelimab in Combination With chemotherapy
- Where
- China
- Volunteers
- 38 people
- Sponsor
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Cholangiocarcinoma
Comparison of Endoscopic Radiofrequency Ablation Versus Photodynamic Therapy for Inoperable Cholangiocarcinoma
The purpose of this study is to compare endoscopic radiofrequency ablation with photodynamic therapy for inoperable cholangiocarcinoma
- Trial name
- NCT01739465
- Testing
- Self expanding metallic stent (SEMS), Endoscopic radiofrequency ablation (ERFA), Photodynamic therapy (PDT)
- Where
- 2 sites in China
- Volunteers
- 120 people
- Sponsor
- Guangzhou Medical University
Advanced Intrahepatic Cholangiocarcinoma
Personalized Tumor Neoantigen mRNA Therapy for Advanced Intrahepatic Cholangiocarcinoma
The main purpose of this study is to evaluate the feasibility and safety of personalized tumor neoantigen mRNA therapy iNeo-Vac-R01 combined with PD-1 monoclonal antibody and standard chemotherapy regimen for the treatment of…
- Trial name
- NCT06956716
- Testing
- individualized anti-tumor new antigen iNeo-Vac-R01 injection, Gemcitabine + cisplatin (GP), Sintilimab injection
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Zhejiang University
Cholangiocarcinoma, Hilar Lymphadenopathy
A Trial of Percutaneous vs. Endoscopic Drainage of Suspected Klatskin Tumors
The optimal approach to the drainage of malignant obstruction at the biliary hilum remains uncertain. This is a randomized comparative effectiveness study of percutaneous transhepatic biliary drainage (PTBD) vs.
- Conditions
- Cholangiocarcinoma, Hilar Lymphadenopathy, Biliary Stricture
- Trial name
- INTERCPT (NCT03172832)
- Testing
- PTBD, ERC
- Where
- 25 sites in United States
- Volunteers
- 13 people
- Sponsor
- Medical University of South Carolina
Liver Cancer, Recurrence
Factors Influencing the 3-Year Recurrence of Liver Carcinoma After Surgery
Objective: 1. To study the factors that influence the 3- year recurrence of liver carcinoma after surgery 2. To study the related factors affecting recurrence of liver carcinoma after surgery
- Trial name
- NCT02941861
- Testing
- Recurrence Rate of HCC after surgery, Recurrence Rate of CCA after surgery
- Volunteers
- 67 people
- Sponsor
- Ruechuta Molek
Biliary Tract Cancer, Cholangiocarcinoma
CisPlatin plUs Gemcitabine and Nabpaclitaxel (GAP) as pReoperative Chemotherapy Versus Immediate Resection in patIents With resecTable BiliarY Tract Cancers (BTC) at High Risk for Recurrence
PURITY is a multicentre, randomized adaptive phase II/III trial aimed at comparing the triplet combination of gemcitabine, cisplatin and nabpaclitaxel as neoadjuvant treatment (ARM A) versus standard upfront surgery (ARM B) in…
- Trial name
- PURITY (NCT06037980)
- Testing
- Gemcitabine, Nab paclitaxel, Cisplatin
- Where
- 19 sites in Italy
- Volunteers
- 300 people
- Sponsor
- Gruppo Oncologico del Nord-Ovest
Advanced Cholangiocarcinoma, FGFR2 Fusions
Study of Futibatinib in Patients With Advanced Cholangiocarcinoma With FGFR2 Fusion or Rearrangement
This is an open-label, multinational, randomized Phase 2 study confirming the clinical benefit of 20 mg futibatinib and evaluating the safety and efficacy of 16 mg futibatinib in previously treated CCA harboring FGFR2 gene…
- Conditions
- Advanced Cholangiocarcinoma, FGFR2 Fusions, Gene Rearrangement
- Trial name
- FOENIX-CCA4 (NCT05727176)
- Testing
- TAS-120
- Where
- 65 sites in United States, Argentina and 11 more
- Volunteers
- 120 people
- Sponsor
- Taiho Oncology, Inc.
Acinar Cell Adenocarcinoma of the Pancreas, Adenocarcinoma of the Gallbladder
Genotype-guided Dosing of mFOLFIRINOX Chemotherapy in Patients With Previously Untreated Advanced Gastrointestinal Malignancies
This study is being done to determine the dose of a chemotherapy drug (irinotecan [irinotecan hydrochloride]) that can be tolerated as part of a combination of drugs.
- Conditions
- Acinar Cell Adenocarcinoma of the Pancreas, Adenocarcinoma of the Gallbladder, Adenocarcinoma of Unknown Primary, Adult Primary Cholangiocellular Carcinoma
- Trial name
- NCT01643499
- Testing
- oxaliplatin, irinotecan hydrochloride, leucovorin calcium
- Where
- 2 sites in United States
- Volunteers
- 79 people
- Sponsor
- University of Chicago
Advanced Cholangiocarcinoma, FGFR2 Gene Mutation
A Phase II, Single Arm Study of BGJ398 in Patients With Advanced Cholangiocarcinoma
This is a multi-center, open label, single arm phase II study evaluating BGJ398 (infigratinib) anti-tumor activity in advanced or metastatic cholangiocarcinoma patients with fibroblast growth factor receptor (FGFR) genetic…
- Trial name
- NCT02150967
- Testing
- BGJ398 (infigratinib)
- Where
- 37 sites in United States, Belgium and 9 more
- Volunteers
- 143 people
- Sponsor
- QED Therapeutics, a BridgeBio company
FGFR2 Amplification, FGFR2 Gene Mutation
REFOCUS: A First-in-Human Study of Highly Selective FGFR2 Inhibitor, RLY-4008, in Patients With ICC and Other Advanced Solid Tumors
This is a Phase 1/2, open-label, FIH study designed to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PDy), and antineoplastic activity of RLY-4008, a potent and highly selective FGFR2 inhibitor, in…
- Conditions
- FGFR2 Amplification, FGFR2 Gene Mutation, FGFR2 Gene Fusion/Rearrangement, FGFR2 Gene Translocation
- Trial name
- NCT04526106
- Testing
- RLY-4008
- Where
- 48 sites in United States, Australia and 11 more
- Volunteers
- 490 people
- Sponsor
- Elevar Therapeutics
Cancer
Trastuzumab Plus R115777 in Treating Patients With Advanced or Metastatic Cancer
Phase I trial to study the effectiveness of trastuzumab plus R115777 in treating patients who have advanced or metastatic cancer.
- Trial name
- NCT00005842
- Testing
- trastuzumab, tipifarnib
- Where
- 2 sites in United States
- Volunteers
- 24 people
- Sponsor
- National Cancer Institute (NCI)
Cholangiocarcinoma
RRx-001 in Second Line Treatment of Advanced Cholangiocarcinoma Prior to Readministration of First-Line Therapy
The purpose of this study is to see if the investigational drug, RRx-001, an epigenetic agent, which turns on a number of beneficial genes that the tumor has silenced, can resensitize the tumor(s), in other words make it/them…
- Trial name
- EPIC (NCT02452970)
- Testing
- RRx-001, Gemcitabine and cisplatin
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- EpicentRx, Inc.
Hepatocellular Carcinoma, Hilar Cholangiocarcinoma
Optimization of Health Expenditure in Liver Surgery
The aim of this study is to reduce the length of stay after liver surgery by taking account of objective quantitative clinical variables, subjective qualitative clinical variables and non clinical variables.
- Conditions
- Hepatocellular Carcinoma, Hilar Cholangiocarcinoma, Intra Hepatic Cholangiocarcinoma, Liver Metastasis
- Trial name
- NCT01715402
- Testing
- liver surgery
- Where
- 11 sites in France
- Volunteers
- 3,000 people
- Sponsor
- Centre Hospitalier Universitaire, Amiens
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.